Making Great Strides towards the Welfare of Humanity

Pioneering healthcare for humanity, Mundipharma is bent on its mission of making innovative medicines accessible to all those in need. Under the quintessential leadership of Mr. Raman Singh, it has emerged as one of the fastest growing pharmaceutical businesses in the world

Efficiently spearheaded by CEO, Mr. Raman Singh, a highly experienced healthcare veteran who brings in more than 2 decades of industry experience, Mundipharma is consistently setting new benchmarks of success in the pharmaceutical industry. Focused on transforming Mundipharma’s business, he has played a significant role in dramatically increasing the size of the organization in terms of its geographic footprint, number of employees, portfolio of medicines and performance.

Prioritizing Patients

Even though the firm has achieved 24 consecutive quarters of growth, yet at the same time, Mundipharma abides by its core value of keeping patients at the heart of everything it does. The geographic expansion – from operating in 12 countries to now having a presence in over 120 – indicates that the organization touches the lives of more patients than ever before. Mundipharma entities cover pharmaceutical markets in Asia-Pacific, Latin America, Middle East and Africa. The headquarters for these territories is in Singapore.

With a mission of alleviating the suffering of patients and to substantially improve their quality of life, Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease &consumer healthcare.

The organisation’s R&D is led from research centres in Singapore, USA, UK, Germany, China and Japan and it carries out pre-clinical research, pharmaceutical development, clinical development, drug safety, regulatory affairs & scientific support of new treatments. Mundipharma also leverages a network of world-class manufacturing facilities & benefits from vertical integration, which in turn benefits patients. Currently, the firm is in the process of opening a new global R&D, manufacturing & distribution facility in Singapore for its range of consumer healthcare products that sit under the umbrella of the iconic BETADINE® brand.

Mr. Singh believes that by fully harnessing the power of innovative new technology, Mundipharma will be able to help even more patients. Thus, Mundipharma launched breatheriteTM, an innovative mobile app that employs augmented reality technology to address errors in inhaler use among Asthma sufferers.